Teva Pharmaceutical has priced a multi-tranche senior notes offering totaling approximately $4.9 billion equivalent, consisting of both U.S. Dollar and Euro-denominated notes. The company plans to use the net proceeds, along with cash on hand, to redeem several series of its existing senior notes, pay related fees and expenses, and for general corporate purposes.
Key Details
- Total Offering: Approximately $4.9 billion (equivalent) across five tranches of senior notes.
- Offering Breakdown:
- €1.0 billion of 4.250% Senior Notes due 2033
- €500 million of 4.625% Senior Notes due 2036
- $1.0 billion of 5.500% Senior Notes due 2034
- $1.0 billion of 5.750% Senior Notes due 2037
- $1.2 billion of 5.250% Senior Notes due 2032
- Closing Date: The sale of the securities is expected to close on September 16, 2026.
- Use of Proceeds: The primary use of funds is to finance the redemption of certain existing notes, effectively refinancing its debt.